PerkinElmer Dives Into Chinese MDx Market with Shanghai Haoyuan Acquisition | GenomeWeb

NEW YORK (GenomeWeb News) – PerkinElmer has acquired Chinese infectious disease diagnostics company Shanghai Haoyuan Biotech for $38 million plus other considerations, the Waltham, Mass.-based firm announced after the close of the market on Monday.

The deal, PerkinElmer said, extends its capabilities into nucleic acid blood screening and in the growing molecular clinical diagnostics market in China, "further strengthening the company's position as a diagnostics leader in China as well as across the globe."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.